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Abstract
Background: Human osteosarcoma is the most common pediatric bone tumor. There is limited understanding of the 
molecular mechanisms underlying osteosarcoma oncogenesis, and a lack of good diagnostic as well as prognostic 
clinical markers for this disease. Recent discoveries have highlighted a potential role of a number of genes including: 
RECQL4, DOCK5, SPP1, RUNX2, RB1, CDKN1A, P53, IBSP, LSAMP, MYC, TNFRSF1B, BMP2, HISTH2BE, FOS, CCNB1, and CDC5L.
Methods: Our objective was to assess relative expression levels of these 16 genes as potential biomarkers of 
osteosarcoma oncogenesis and chemotherapy response in human tumors. We performed quantitative expression 
analysis in a panel of 22 human osteosarcoma tumors with differential response to chemotherapy, and 5 normal 
human osteoblasts.
Results: RECQL4, SPP1, RUNX2, and IBSP were significantly overexpressed, and DOCK5, CDKN1A, RB1, P53, and LSAMP 
showed significant loss of expression relative to normal osteoblasts. In addition to being overexpressed in 
osteosarcoma tumor samples relative to normal osteoblasts, RUNX2 was the only gene of the 16 to show significant 
overexpression in tumors that had a poor response to chemotherapy relative to good responders.
Conclusion: These data underscore the loss of tumor suppressive pathways and activation of specific oncogenic 
mechanisms associated with osteosarcoma oncogenesis, while drawing attention to the role of RUNX2 expression as a 
potential biomarker of chemotherapy failure in osteosarcoma.
Background
Osteosarcoma is the most common pediatric tumor of
the bone. Clinically, osteosarcoma has a bimodal distri-
bution, with the majority of patients developing the dis-
e a s e  d u r i n g  t h e  p e r i o d  o f  a c t i v e  b o n e  g r o w t h  i n  e a r l y
adolescence. The treatment generally involves surgery,
often involving a loss of limb, and adjuvant chemother-
apy. The best prognostic marker for osteosarcoma is the
response to chemotherapy, where good response to che-
motherapy is associated with an overall more favorable
patient outcome and survival [1,2].
At the molecular level osteosarcoma is characterized by
a high level of genomic instability, highly heterogenous
karyotypes both intra- and inter-tumor, and gross
changes in gene expression [3-9]. Human osteosarcoma
tumors often have osteoblast-like features but may vary
within a broad range of epithelial mesenchymal lineages
reflective of their poorly differentiated phenotype [10-
12]. Therefore, assessment of the molecular changes in
osteosarcoma tumors relative to normal osteoblasts can
provide important insights concerning gene expression
changes associated with both osteosarcoma oncogenesis
and with molecular alterations governing differential
clinical response to treatment.
The genetic change most commonly associated with
osteosarcoma is the loss of the TP53 tumor suppressor
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gene through either genetic mutation or loss of gene
expression [13-15]. Patients with Li-Fraumeni syndrome,
which results from loss of TP53, have a strong predisposi-
tion to developing osteosarcoma [16]. Another tumor
suppressor gene whose loss of expression is linked to
osteosarcoma is RB1 [17]. In our recent studies, we have
also shown that these genes play a central role in osteo-
sarcoma-related gene expression networks both in
human osteosarcoma cell lines [18] and tumor tissues
[19]. We used a unique bioinformatic integrative whole-
genome approach to map the genetic and epigenetic
changes in osteosarcoma tumors and to identify gene net-
works related to osteosarcoma oncogenesis. Changes that
showed the most significant associations with osteosar-
coma gene networks included: overexpression and the
most significant copy number gain of the chromosome
6p21.1 RUNX2 locus, loss of expression and genomic loss
of the DOCK5  and  TNFRSF10A  loci at chromosome
8p21.1-21.3, and hypomethylation, copy number gain,
and overexpression of the HISTH2BE gene at chromo-
some 1q21. Other genes that showed deregulated expres-
sion and significant contribution to osteosarcoma gene
networks included overexpressed SPP1, IBSP, BMP2, and
c-MYC, and uderexpressed CDKN1A,  LSAMP, and
CCNB1. Another gene that is thought to play a role in
osteosarcoma and has been shown to be overexpressed is
the FOS proto-oncogene [20,21]. Similarly, CDC5L has
been recently proposed as the putative oncogene at the
6p21 locus in osteosarcoma [22]. Finally, a DNA repair
gene, RECQL4, has been shown to be overexpressed, and
its level of overexpression correlates with overall genomic
instability in osteosarcoma [23].
Microarray analysis and reverse-transcriptase poly-
merase chain reaction (RT-PCR) are useful for the molec-
ular classification of tumors and for deriving biological
mechanisms that underpin differential prognosis for
patients with various types of cancer, including osteosar-
coma [24-27]. The use of gene-expression profiling in
clinical practice is however limited by the large number
of genes that need to be analyzed and by the lack of
reproducibility of various array platforms and interpreta-
tive methods [28]. Quantitative RT-PCR methods can be
readily applied to RNA derived from formalin-fixed, par-
affin-embedded (FFPE) pathological specimens, are
reproducible and may be highly applicable in clinical
practice [29], particularly for a rare tumor such as osteo-
sarcoma in which access to frozen tissue is often limited.
RT-PCR can only typically be used to analyze a small
number of genes. Therefore it is important to select gene
subsets for detailed analyses in which multiple lines of
evidence implicate clinical utility. In previous studies, we
[18,19], and others [22,30,31] have performed microarray
analyses of osteosarcoma cell lines and tissue samples and
identified a series of genes with strong potential as bio-
markers with clinical utility. Thus, the objective of the
current study was to examine expression profiles of
RECQL4, DOCK5, SPP1, RUNX2, RB1, CDKN1A, TP53,
IBSP,  LSAMP,  MYC,  TNFRSF1B,  BMP2,  HISTH2BE,
FOS, CCNB1, and CDC5L genes in a cohort of osteosar-
coma tumors and normal human osteoblasts. As a result,
we show that RECQL4, SPP1, RUNX2, and IBSP are sig-
nificantly overexpressed, and DOCK5,  CDKN1A,  RB1,
P53, and LSAMP show significant loss of expression rela-
tive to normal osteoblasts. We also show that RUNX2 was
the only gene with significant overexpression in tumors
with an unfavorable response to chemotherapy relative to
favorable responders.
Methods
Tissue samples
The collection of frozen tissue specimens (n = 15), archi-
val formalin-fixed, paraffin-embedded osteosarcoma sec-
tions (n = 7), and clinicopathological data was obtained
and handled in accordance with the Hospital for Sick
Children Research Ethics guidelines (Toronto, Canada).
This was a retrospective study of chemotherapy-naive
biopsy samples collected sequentially between 1996 and
2005, and all specimens presented a tumor content
higher than 90%. All patients were subjected during treat-
ment to standard regimens for osteosarcoma, comprising
cisplatin, doxorubicin, and methotrexate. The patient
tumor specimens were revised at the time of study by the
pathologist (P.T.). The details of the cases are presented in
Table 1. The Huvos grading system was used to rate the
level of tumor necrosis following preoperative chemo-
therapy: Grade I, little or no effect of chemotherapy
noted; Grade II, partial response to chemotherapy, with
between 50% and 90% necrosis; Grade III, greater than
90% necrosis; and Grade IV, no viable tumor cells are
apparent [32]. The good responders are patients with
necrosis ≥ 90% [33]. Normal human osteoblasts that were
isolated from surgical bone specimens from five healthy
individuals were obtained from Promocell (Heidelberg,
Germany).
RNA isolation
Total RNA from snap-frozen tissue (5 normal human
osteoblasts and 15 tumors) was extracted and purified
using the TRIzol Reagent method according to the manu-
factures protocol (Invitrogen, Carlsbad, CA, USA). FFPE
tissues (7 tumors) were deparaffinized with xylene,
was h ed  wi t h  E T O H ,  a n d  d i g e s t ed  wi t h  a  p r o t e i n as e  K
buffer [34]. Total RNA was extracted and purified as
above with TRIzol reagent. The RNA quality was good
for all samples as assessed by BioAnalyzer RNA 600 Nano
Kit (Agilent Technologies, Palo Alto, CA). Additionally,
the overall trends for expression in tumors relative to
normal osteoblasts were similar in frozen and FFPE sam-Sadikovic et al. BMC Cancer 2010, 10:202
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ples corroborating the quality of the extracted RNA
(Additional file 1).
Quantification of mRNA Expression
Quantitative real-time PCR (qRT-PCR) was used to
quantify mRNA expression levels of 16 genes (RUNX2,
DOCK5,  TNFRS1B,  HISTH2BE,  P21,  SSP1,  P53,  IBSP,
CCNB1, BMP2, LSAMP, RB1, FOS, MYC, RECQL4, and
CDC5L). Briefly, 1-2 ug of total RNA was converted to
cDNA using GeneAmp Gold RNA PCR Core Kit
(Applied Biosystems, Foster City, CA, USA), as per man-
ufacturers recommendations. Primers were designed to
specifically amplify templates of approximately 90-130
nucleotides overlapping exon boundaries of 3' terminal
exons using the Primer-Blast software http://
www.ncbi.nlm.nih.gov/tools/primer-blast/. The primers
were subsequently tested by both PCR and qRT-PCR for
specificity and single band amplification. The sequences
of the PCR primer pairs used for each gene are shown in
Additional file 2. The qRT-PCR assays for a particular
gene were undertaken at the same time for all samples
under identical conditions, in duplicate. The cycling con-
Table 1: Descriptive and histopathological features of the tumor cohort and normal osteoblasts.
Sample Huvos grade Group Age Sex Site Histology
HOB A NA Normal NA M femur osteoblasts 
normal
HOB B NA Normal NA M femur osteoblasts 
normal
HOB C NA Normal NA F femur osteoblasts 
normal
HOB D NA Normal NA M femur osteoblasts 
normal
HOB E NA Normal NA M femur osteoblasts 
normal
176 III Good 7 M humerus chondroblastic
177 III Good 10 M femur chondroblastic
186 III Good 7 F humerus osteoblastic
255 III Good 9 M tibia osteoblastic
259 III Good 7 M femur osteoblastic
260 III Good 14 F femur osteoblastic
214 IV Good 4 F femur osteoblastic
217 III Good 10 F tibia osteoblastic
220 IV Good 12 M tibia fibroblastic
223 III Good 12 F humerus osteoblastic
230 III Good 12 F fibula osteoblastic
174 II Poor 14 M femur osteoblastic
178 I Poor 5 F humerus osteoblastic
179 I Poor 11 F tibia osteoblastic
182 I Poor 13 M femur osteoblastic
183 II Poor 12 F femur poorly differ.
187 I Poor 6 F femur osteoblastic
234 II Poor 13 M femur osteoblastic
254 I Poor 7 M humerus osteoblastic
256 I Poor 15 M femur poorly differ.
261 I Poor 13 M femur osteoblastic
211 I Poor 12 F femur osteoblasticSadikovic et al. BMC Cancer 2010, 10:202
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ditions were as follows: 95°C for 2 min, 40 cycles of 95°C
for 15 sec and 60°C for 45 sec, with a final extension 72°C
for 5 min.
T h e  m RN A  e x p r e s s i o n  l ev e l s  w e r e  d e t e rm i n ed  u s i n g
Platinum SYBR Green qPCR Supermix-UDG with Rox
(Invitrogen, Carlsbad, CA, USA), and the Applied Biosys-
tems Prism 7900 Sequence Detection System (PE Applied
Biosystems, Inc., Foster City, CA). The relative expression
level of the genes of interest was computed relative to the
endogenous control, phosphoglycerate kinase (PGK), to
normalize for variances in the quality of RNA and the
amount of input cDNA. Additionally, we validated our
experimental conditions by analyzing the expression of
two genes identified in our previous microarray study
[19]; A2M, the highest overexpressing gene of the set and
our positive control for the current study; and SLC14A,
the gene with the lowest expression of the set and our
negative control for the current study (Additional file 3).
The mRNA expression levels for each sample were deter-
mined as fold-change values relative to the mean baseline
expression levels for five human osteoblasts (HOBs),
using the delta delta Ct method of analysis [35].
Statistical analysis
Results of the delta-delta Ct analysis were log10 trans-
formed and imported to Partek Genomic Suite software
(Additional file 1). The tumor samples were grouped by
Huvos grade into those with favorable response to che-
motherapy (Grades I and II) and unfavorable response
(Grades III and IV); and were compared either as a group
to normal human osteoblasts (i.e. tumor vs. normal), or
to each other (i.e. unfavorable vs. favorable). Differences
in p-values between groups were obtained using the non-
parametric rank-sum Mann-Whitney test, and fold
change differences between groups were obtained using
the 1-way ANOVA tool (Additional file 4) using the
Partek Genomic Suite software. This study was designed
as a confirmatory analysis based on specific genes that
were previously shown to have significant expression
changes in steosarcoma, and thus multiple test correction
was not applicable [36]. This analysis is designed to assess
the correlation of specific gene expression as an individ-
ual parameter against the ostosarcoma phenotype, and is
not meant to assess these genes as a group, gene network,
or a multiple gene signature.
Results
The pathology of 22 osteogenic sarcomas and follow-up
biopsies were analysed to determine response to chemo-
therapy and percent of necrotic tissue. This allowed
tumors to be grouped as good responders (Huvos grades
III and IV with favorable responses to chemotherapy) and
poor responders (Huvos grades I and II with unfavorable
responses to chemotherapy) (Table 1). Eleven tumors
were identified to have 95% or more necrosis as a result of
chemotherapy and were labelled as favorable responders,
and the remaining 11 tumors were characterized as unfa-
vorable responders. The baseline control consisted of a
panel of five normal human osteoblast samples. The
majority of tumors displayed osteoblastic histology, and
most tumors and all osteoblast controls were of femoral
origin.
In order to quantitatively assess the expression of the
target genes (RECQL4,  DOCK5,  SPP1,  RUNX2,  RB1,
CDKN1A,  TP53,  IBSP,  LSAMP,  MYC,  TNFRSF1B,
BMP2, HISTH2BE, FOS, CCNB1, and CDC5L) we per-
formed qRT-PCR on the tumor cohort and human osteo-
blast samples (Additional file 1). Statistical analysis of
these data revealed significant changes in a number of
genes (Table 2). Tumors displayed significant overexpres-
sion of RECQL4, SPP1, RUNX2, and IBSP genes and loss
of expression of DOCK5,  CDKN1A,  RB1,  TP53, and
LSAMP (p < 0.05) (Figure 1). The highest level of overex-
pression was measured in SPP1 with 113-fold overexpres-
sion, while the largest reduction of expression of 36-fold
was evident in the DOCK5 gene. Comparison of tumors
with unfavorable response to ch emotherapy to favorable
responders revealed RUNX2 as the only significant gene
(p = 0.03). On average unfavorable responders to chemo-
therapy showed 3.3-fold increase in the RUNX2  gene
expression relative to favorable responders. Furthermore,
RUNX2 expression showed a trend towards overexpres-
sion going from normal osteoblasts to favorable respond-
ers to chemotherapy and then to unfavorable responders
to chemotherapy (Figure 1). The tumor sample #256 that
exhibited the worst response to chemotherapy, also
showed highest levels (113-fold) of RUNX2 overexpres-
sion (Additional file 1).
The remaining genes showed no significant changes in
expression in tumors relative to normal osteoblasts.
MYC, BMP2, and FOS show an associative trend when
overexpressed, and TNFRSF10A shows a trend in under-
expression in the tumor cohort. Notably, CDC5L showed
essentially no change in expression levels relative to nor-
mal osteoblasts.
Discussion
Transformation of normal cells and initiation of tumori-
genesis involves a combination of genetic and epigenetic
changes [37]. Progressive acquisition of such changes
ultimately results in destabilization of the genome, dereg-
u l a t i o n  o f  g e n e  e x p r e s s i o n  p a t h w a y s  a n d  a c t i v a t i o n  o f
oncogenic gene expression networks. Identification of
key genes, or network "nodes", will provide a more com-
prehensive understanding of tumorigenic processes, and
provide more effective diagnostic, prognostic and thera-
peutic markers. In our recent integrative epi/genomic
studies of osteosarcoma cell lines [18] and tumorSadikovic et al. BMC Cancer 2010, 10:202
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genomes [19] we identified a number of such genes. A
survey of the current literature allowed us to augment
this list to a total of sixteen genes whose expression levels
were assessed in an expanded tumor cohort. By compar-
ing the gene expression levels to a panel of normal human
osteoblasts, it allowed us to identify changes that are
likely to be involved in osteosarcoma tumorigenesis. As a
result, we identified significant disruptions of gene
expression in nine of these genes, including loss of
expression of DOCK5, CDKN1A, RB1, TP53, and LSAMP
genes, and overexpression of RECQL4,  SPP1,  RUNX2,
and IBSP genes.
Our study demonstrates a significant deregulation of
proteins in osteosarcoma that are important effectors in
the cell cycle and in differentiation. Significantly, we
detected loss of TP53 expression, which may also play a
role in loss of expression of CDKN1A, which encodes the
cyclin-dependent kinase inhibitor 1A (p21) and whose
expression is activated by p53 [38]. Loss of DOCK5 may
play a similar role as it was shown recently that DOCK5
expression is essential for bone differentiation, from pre-
cursor osteoclasts [39]. Interestingly, in our recent study
we showed that DOCK5 is located in the most significant
region of copy number loss in osteosarcoma 8p21.2-p21.3
[19] along with the TNFRSF10A gene, for which we see
an overall trend of loss of expression in our current study.
TNFRSF10A is a receptor activated by tumor necrosis
factor-related apoptosis inducing ligand TNFSF10 (also
known as TRAIL), and is involved in the transduction of
cell death signal and induction of cell apoptosis, which is
mostly independent of p53 signalling [40].
A significant region of copy number loss at 3q13.31 has
been identified in our previous study [19], and has also
been observed by another group in 56% of osteosarco-
mas. This region of copy number loss was shown to cor-
relate with loss of expression and hypermethylation of the
LSAMP  gene, and the authors proposed LSAMP as a
novel tumor suppressor in osteosarcoma [31]. Our data
agree with these findings and show significant loss of
expression of LSAMP in the majority of our osteosar-
coma samples. LSAMP codes for a neuronal surface gly-
coprotein found in cortical and subcortical regions of the
limbic system, but it is currently unclear how this gene
may be related to osteosarcoma tumorigenesis.
RUNX2 was one of the genes overexpressed in our set
of tissue samples, and the only gene whose overexpres-
sion was significantly related to poor response to chemo-
therapy in osteosarcomas. RUNX2 is a member of the
Runx transcription factor family consisting of RUNX1,
RUNX2, and RUNX3 which function in the development
of a number of tissues [41]. Of the three proteins, both
RUNX1 and RUNX2 have been associated with oncogen-
esis. RUNX1 and RUNX2 upregulate LGALS3 (galectin-
3) [42], a protein which suppresses anoikis and drug-
Table 2: Statistical evaluation of the tumor-specific and chemotherapy response-related gene expression signatures.
Gene Tumor vs. Normal Poor vs Good References
p-value fold change p-value fold change
RECQL4 0.00087 10.16 0.84739 -1.14 [22]*
DOCK5 0.00094 -36.81 0.86960 -1.58 [18]
SPP1 0.00180 113.97 0.57674 -1.21 [18]
RUNX2 0.00222 7.13 0.02782 3.30 [18]
RB1 0.00252 -14.87 0.14164 5.14 [16]
CDKN1A 0.00409 -8.61 0.71798 1.27 [18]
P53 0.00409 -20.63 0.45016 1.65 [12-15]
IBSP 0.03382 9.61 0.45016 -1.25 [18]
LSAMP 0.04278 -11.56 0.14164 4.42 [18]
MYC 0.05492 3.05 0.56370 1.61 [17]
TNFRSF10A 0.07359 -2.34 1.00000 -1.07 [18]
BMP2 0.10975 3.86 0.36911 2.21 [18]
HISTH2BE 0.26121 1.30 0.97381 1.10 [18]
FOS 0.33725 2.34 0.56763 2.95 [19,20]
CCNB1 0.41368 -1.20 0.46243 -1.03 [18]
CDC5L 0.90645 -1.13 0.63043 -1.98 [21]
*References are to the original papers describing the change in expression in these genes in osteosarcomaSadikovic et al. BMC Cancer 2010, 10:202
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Figure 1 Expression analysis of osteosarcoma-related genes. qRT-PCR levels of gene expression of 16 osteosarcoma-related genes in 5 normal 
human osteoblasts and 22 human osteosarcoma samples are shown on y-axis. The samples are grouped based on the response to chemotherapy 
status on y-axis. Corresponding box and whiskers plots representing the mean, 25th and 75th percentile (boxes), and 10th and 90th percentile (whiskers) 
are also shown. From left to right, and top to bottom of the panel, the plots are placed in the order of Mann-Whitney p-value significance (tumor vs. 
normal). HOB: normal human osteoblasts; Good: Favorable response to chemotherapy (Huvos grades III and IV); Poor: Unfavorable response to che-
motherapy (Huvos grades I and II).
1
0
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induced apoptosis [43] and whose expression is corre-
lated with metastasis in osteosarcoma [44] and progres-
sion in glioma [45]. Similarly, in lymphoma,
overexpression of RUNX2 and MYC results in the "collab-
oration" of the two corresponding proteins to attenuate
apoptosis and promote proliferation [46]. In developing
osteoblasts, expression of RUNX2  normally decreases
during maturation [47], and overexpression of the gene
leads to a higher rate of bone turnover [48]. In bone met-
astatic breast cancer, RUNX2 promotes cancer cell sur-
vival and growth by activating expression of IHH  and
interacts with the TGFβ/BMP signal transduction path-
way to parathyroid hormone-related protein (PTHrP)
[49]. Thus the finding of elevated expression of RUNX2 in
osteosarcomas with an unfavorable chemotherapy
response is consistent with its oncogenic potential noted
in other studies
In addition to RUNX2, three other genes, SPP1,
RECQL4, and IBSP  showed significant overexpression.
SPP1 (osteopontin), like RUNX2, is a member of the
BMP-signalling protein family. It shows the highest over-
expression (113-fold) in our analysis, and has previously
been shown to be significantly overexpressed in osteosar-
coma tumors [50] and cell lines [51]. Antisense knock-
down of SPP1  RNA in osteosarcoma cells results in
inhibition of in vivo tumorigenesis in mice. These find-
ings suggest that overexpression of SPP1 plays a role in
osteosarcoma tumorigenesis, in particular, in cells lacking
expression of cell cycle regulators and differentiation-
related genes, as discussed earlier. RECQL4  is a gene
whose protein product is involved in repair of DNA dou-
ble stranded breaks and deregulation of its expression
was recently shown to be strongly correlated with
genomic instability in osteosarcoma [23]. Our data are
consistent with this in further reaffirming the association
of  RECQL4  overexpression with osteosarcoma tumori-
genesis. The final gene which showed significant overex-
p r e s s i o n  i n  t u m o r s  r e l a t i v e  t o  n o r m a l  c e l l s ,  IBSP, also
known as bone sialoprotein, is a marker of terminal dif-
ferentiation of bone. In normal osteoblasts RUNX2 and
HDAC3 have been shown to suppress IBSP, and upon ter-
minal differentiation loss, of RUNX2 expression dere-
presses IBSP and allows for terminal differentiation [52].
In tumors, however, although IBSP  shows significant
overexpression relative to osteoblasts, concurrent overex-
pression of RUNX2 indicates possible disruption of the
terminal differentiation process.
By comparing our tumor panel, the majority of which
(17/22) are the osteoblastic histological subtype, we iden-
tified gene expression changes associated with osteosar-
coma oncogenesis. However, a possible limitation of this
study is that some of the genetic associations described
may not be present in osteosarcoma lineages that arise
from more primitive cells of origin, including mesenchy-
mal precursors [53-55]. In addition to the associations of
gene expression with oncogenesis, we showed that the
RUNX2 gene displays significant increase in expression in
tumors with poor response to chemotherapy relative to
the good responders. Our results may be reflective of
either increased levels of gene expression in individual
tumor cells during disease progression, or alternatively an
increased proportion of cell lineages with RUNX2 expres-
sion in these genetically highly heterogenous cells. Both
scenarios would allow selective advantage to the evolving
cell lineages during tumorigenesis. Detailed immunohis-
tochemical and imaging experiments will be required to
further delineate these possibilities. It also remains to be
determined if this correlation is evident at the protein
level, and if so, RUNX2 may be a good histological
marker for chemotherapy response, which is currently
the best predictor of overall outcome in patients with
osteosarcoma.
Conclusion
These data underscore the loss of tumor suppressive
pathways the deregulation of cell cycle control proteins,
and the activation of specific oncogenic mechanisms
associated with osteosarcoma oncogenesis. Our results
also draw attention to the role of RUNX2 expression as a
potential biomarker of chemotherapy failure in osteosar-
coma.
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